
Stroke rehabilitation: why 94% of patients get less than NICE recommends
Inna Oleksiienko | Editorial Contributor
11-minute read | 17/11/2026


New results suggest that the benefits of the Alzheimer's drug lecanemab may keep building the longer people take it, over five years of treatment. The findings were shared on 16 November 2026.
Lecanemab is licensed in the UK, but it isn't available on the NHS. Here we explain what the new results show, why they matter, and what they could mean for people in the early stages of Alzheimer's and their families.
On 16 November 2026, the drug's makers, Eisai and Biogen, presented new results at the Clinical Trials on Alzheimer's Disease conference, held in Boston and online. The results followed 351 people who had taken lecanemab without a break for five years. This five-year period includes the original 18-month trial, called Clarity AD, and another three and a half years in a follow-up study.
After the original trial, 95% of people who completed it chose to carry on in the follow-up study, where everyone took lecanemab. So there was no placebo group to compare with at five years. Instead, the makers compared them with outside research data, from studies called ADNI and BioFINDER, on how Alzheimer's usually progresses.
Clarity AD was an international trial, run at 235 sites across North America, Europe and Asia. The five-year group is made up of people from this trial who carried on in the follow-up study.
The makers reported that:
These results come from a conference presentation and the companies' own announcement, rather than a paper in a medical journal.
Lecanemab (brand name Leqembi) was the first disease-modifying treatment approved for use in the UK for early Alzheimer's, meaning it aims to slow the disease rather than only ease symptoms. It binds to amyloid, a protein that builds up in the brain in people with Alzheimer's, to help clear it.
In the original 18-month trial, called Clarity AD, 1,795 people with early Alzheimer's took either lecanemab or a dummy treatment (placebo). Lecanemab slowed decline by 27% compared with the placebo. NICE estimated this means slowing progression by about four to six months.
It's an important step, but lecanemab isn't a cure, and it won't be suitable for everyone. Here's who it's licensed for and what treatment involves:
Long-term results take years to collect. The original trial lasted 18 months, and researchers have shared updates from the follow-up study as each new year of data came in.
Not yet. Lecanemab has been licensed in the UK since August 2024. But for the NHS in England and Wales to offer it, NICE needs to recommend it. At the moment, people can only get it privately.
Here's how it has gone so far:
A similar drug, donanemab (brand name Kisunla), was paused in the same way. NICE has estimated that around 70,000 adults in England would have been eligible for treatment with one of these drugs.
The drug isn't available on the NHS anywhere in the UK. But the decision isn't made the same way in every country.
| Country | Who decides | Where things stand | |
|---|---|---|---|
England | NICE | Not recommended. The assessment is paused while Eisai and NHS England discuss a price. | |
Wales | Same as England. | ||
Northern Ireland | NICE decisions are normally adopted | Same as England. | |
Scotland | Scottish Medicines Consortium (SMC) | Not recommended. The SMC said no in February 2025, and again in July 2025 after a second review. |
In Scotland, the SMC pointed to the high cost and uncertainty about how well it works. It said it would welcome a resubmission that deals with those uncertainties. Donanemab was also not recommended in Scotland in February 2026.
Because lecanemab is licensed in the UK, it can be prescribed outside the NHS. Alzheimer's Society says it's available through some private health providers.
It's a specialist treatment with several steps before anyone can start it:
What it costs. The Scottish Medicines Consortium estimated the price of the drug itself at around £21,320 a year. Private treatment costs more, because it also includes specialist tests, regular infusions and brain scans. In July 2025, Alzheimer's Research UK estimated private treatment at £60,000 to £80,000 a year, and said costs vary between providers.
These figures are general estimates, not a recommendation. Each provider sets its own prices, which may have changed since these estimates were published.
Right now, nothing has changed for patients. The new five-year results don't change the drug's NHS status, and it's still only available privately.
Here's what the NHS and the government have said:
Leading dementia specialists and charities are calling for NHS access to these drugs. They're also calling for a maximum 18-week wait for a dementia diagnosis, so people can get treatment as soon as possible.
No date for a decision has been announced. If NICE does recommend lecanemab:
Even then, it may take time for everyone eligible to get it. In June 2025, Alzheimer's Society said that even if the drugs were available on the NHS straight away, too many people couldn't get them because the health system isn't ready to deliver them.
In the US, a version of lecanemab that's injected under the skin has been approved for both starting and continuing treatment. In the US, this lets people have injections at home instead of hospital infusions. In July 2026, UK regulators were expected to decide on it later in the year. US approval doesn't mean it will be approved in the UK.
One of the biggest questions about lecanemab has been whether its benefits last. The original trial lasted 18 months, and the lack of long-term evidence was one of the reasons NICE gave for its decision. The makers say the new results show the benefit continuing to build over time.
NICE's own committee accepted that any slowing of the disease would be meaningful, because it could mean more time socialising, driving and being independent, and needing less day-to-day help from family.
There are important limits to keep in mind:
Price talks between Eisai and NHS England began in July 2026, and no date for a decision has been announced. It's too early to say whether these new results will affect the outcome.
If you have questions about memory problems or about this treatment, a GP is the best person to speak to.
In October 2026, the government announced a £48 million partnership to speed up dementia research and help new treatments reach patients faster.
This article is for general information only and isn't medical advice. Speak to a GP or specialist about any treatment.
This article reflects the situation as of 17 November 2026.
Elder is an introductory agency and therefore does not direct, control, monitor or oversee the ongoing delivery of care. This article is for general information only and is not a substitute for professional advice, which should be sought when appropriate.

Inna Oleksiienko | Editorial Contributor

Inna Oleksiienko | Editorial Contributor

Inna Oleksiienko | Editorial Contributor

Mark Acheson | Editorial Contributor

Mark Acheson | Editorial Contributor

Mark Acheson | Editorial Contributor